Sugi Predict

Sugi Predict / Compounds / SCHEMBL1495939

SCHEMBL1495939

SCHEMBL1495939

COC(=O)c1ccccc1NS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.80
▸ LMNA P02545 7/20 0.78
▸ GAA P10253 3/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ KMT2A Q03164 3/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ HTT P42858 3/20 0.64
▸ HPGD P15428 2/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ TP53 P04637 1/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ TSHR P16473 2/20 0.64
▸ KDM4E B2RXH2 2/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ ELANE P08246 1/20 0.61
▸ PRTN3 P24158 1/20 0.61
▸ NPC1 O15118 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ CYP1A2 P05177 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13011714 0.89 KMT2A (0.74) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL3278881 0.87 LMNA (0.63) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL13999329 0.87 LMNA (0.63) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL13999327 0.87 ELANE (0.63) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL5158052 0.87 LMNA (0.79) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL3283149 0.86 KMT2A (0.69) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL1688339 0.85 METAP2 (0.71) FFAR4LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL3557584 0.84 FFAR4 (0.65) FFAR4LMNAGAAALDH1A1KMT2A
SCHEMBL15821566 0.84 LMNA (0.67) FFAR4LMNAGAAALDH1A1KMT2A
Zinc Ion SCHEMBL9443911 0.84 LMNA (0.67) FFAR4LMNAGAAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4692092-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF Aliad Biopharma (KR) 2026-02-11 — — EP disclosed
WO-2024205377-A1 NOVEL COMPOUNDS WITH MTORC2-INHIBITORY ACTIVITY AND USES THEREOF 알리아드바이오파마 주식회사 2024-10-03 — — WO disclosed
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2024-08-20 — — US disclosed
EP-4140991-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2024-05-15 — — EP disclosed
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. (CN) 2023-05-25 — — US disclosed
EP-4140991-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2023-03-01 — — EP disclosed
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORPORATION 2022-11-17 — — US disclosed
EP-3802514-B1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES PROMEGA CORP (US) 2022-08-03 — — EP disclosed
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes PROMEGA CORPORATION (US) 2022-07-19 — — US disclosed
EP-3802514-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES Promega Corporation (US) 2021-04-14 — — EP disclosed
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia ELI LILLY AND COMPANY (US) 2007-11-01 — — US disclosed
EP-1781661-A2 VASOPRESSIN V1A ANTAGONISTS Ferring B.V. (NL) 2007-05-09 — — EP disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 — — EP disclosed
EP-1632494-A1 Vasopressin v1a antagonists FERRING B.V. (NL) 2006-03-08 — — EP disclosed
WO-2006021213-A2 VASOPRESSIN V1A ANTAGONISTS FERRING B.V. (NL) 2006-03-02 — — WO disclosed
US-6936602-B1 Benzazepine derivatives, process for the preparation of the same and uses thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-30 — — US disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 — — WO disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 — — EP disclosed
EP-1186604-A1 BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-03-13 — — EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159463-A1 BENZONITRIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF HDAC11, HDAC1, HDAC6 FFAR4 1694/4885LMNA 2388/4885GAA 672/4885
US-20220365086-A1 INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885LMNA 1478/4885GAA 937/4885
US-12065421-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885LMNA 1478/4885GAA 937/4885
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia APOB, CETP, PCSK9 FFAR4 236/4885LMNA 416/4885GAA 445/4885
US-11390599-B2 Inhibitors of oplophorus luciferase-derived bioluminescent complexes LUC7L2, LYPLAL1, GUSB FFAR4 4152/4885LMNA 1478/4885GAA 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.